Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections

Christopher J. Destache, S. K. Meyer, M. T. Padomek, B. G. Ortmeier

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The present study was a retrospective, case-control design aimed at evaluating whether the clinical pharmacokinetic service (CPS) is cost-effective, as assessed by lengths of hospital stay and aminoglycoside therapy, incidence of a decrease in renal function, and time for resolution of infection as determined by viral signs. Forty-six patients were entered into this study, and were matched by defined criteria. The results of the study demonstrated a six-day difference in hospital stay for the CPS group (p <0.05). Length of aminoglycoside therapy was 33 hours shorter for the CPS group. Additionally, the time necessary for resolution of the infection was significantly shorter for this group, as assessed by vital signs returning to normal or baseline. Three patients in each group expired. Two patients in the CPS group and five in the control group developed aminoglycoside-associated increases in serum creatinine. No significant difference was found between the two groups in age, weight, or APACHE II score. Additionally, the two groups were similar with respect to concomitant diseases and concomitant antibiotics used. The approximate cost of the CPS was calculated as $56 per patient. Use of the CPS decreasing hospital stay by six days (mean $1875/patient) would translate to an annual savings of $654,375 in hospital charges, assuming 365 patients received aminoglycoside therapy per year.

Original languageEnglish
Pages (from-to)33-38
Number of pages6
JournalDICP, Annals of Pharmacotherapy
Volume23
Issue number1
StatePublished - 1989

Fingerprint

Aminoglycosides
Pharmacokinetics
Length of Stay
Infection
Hospital Charges
Costs and Cost Analysis
APACHE
Vital Signs
Creatinine
Therapeutics
Age Groups
Anti-Bacterial Agents
Kidney
Weights and Measures
Control Groups
Incidence
Serum

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections. / Destache, Christopher J.; Meyer, S. K.; Padomek, M. T.; Ortmeier, B. G.

In: DICP, Annals of Pharmacotherapy, Vol. 23, No. 1, 1989, p. 33-38.

Research output: Contribution to journalArticle

@article{0891a3ec39ba4c7aa08a052f30eb527a,
title = "Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections",
abstract = "The present study was a retrospective, case-control design aimed at evaluating whether the clinical pharmacokinetic service (CPS) is cost-effective, as assessed by lengths of hospital stay and aminoglycoside therapy, incidence of a decrease in renal function, and time for resolution of infection as determined by viral signs. Forty-six patients were entered into this study, and were matched by defined criteria. The results of the study demonstrated a six-day difference in hospital stay for the CPS group (p <0.05). Length of aminoglycoside therapy was 33 hours shorter for the CPS group. Additionally, the time necessary for resolution of the infection was significantly shorter for this group, as assessed by vital signs returning to normal or baseline. Three patients in each group expired. Two patients in the CPS group and five in the control group developed aminoglycoside-associated increases in serum creatinine. No significant difference was found between the two groups in age, weight, or APACHE II score. Additionally, the two groups were similar with respect to concomitant diseases and concomitant antibiotics used. The approximate cost of the CPS was calculated as $56 per patient. Use of the CPS decreasing hospital stay by six days (mean $1875/patient) would translate to an annual savings of $654,375 in hospital charges, assuming 365 patients received aminoglycoside therapy per year.",
author = "Destache, {Christopher J.} and Meyer, {S. K.} and Padomek, {M. T.} and Ortmeier, {B. G.}",
year = "1989",
language = "English",
volume = "23",
pages = "33--38",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "1",

}

TY - JOUR

T1 - Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides for gram-negative infections

AU - Destache, Christopher J.

AU - Meyer, S. K.

AU - Padomek, M. T.

AU - Ortmeier, B. G.

PY - 1989

Y1 - 1989

N2 - The present study was a retrospective, case-control design aimed at evaluating whether the clinical pharmacokinetic service (CPS) is cost-effective, as assessed by lengths of hospital stay and aminoglycoside therapy, incidence of a decrease in renal function, and time for resolution of infection as determined by viral signs. Forty-six patients were entered into this study, and were matched by defined criteria. The results of the study demonstrated a six-day difference in hospital stay for the CPS group (p <0.05). Length of aminoglycoside therapy was 33 hours shorter for the CPS group. Additionally, the time necessary for resolution of the infection was significantly shorter for this group, as assessed by vital signs returning to normal or baseline. Three patients in each group expired. Two patients in the CPS group and five in the control group developed aminoglycoside-associated increases in serum creatinine. No significant difference was found between the two groups in age, weight, or APACHE II score. Additionally, the two groups were similar with respect to concomitant diseases and concomitant antibiotics used. The approximate cost of the CPS was calculated as $56 per patient. Use of the CPS decreasing hospital stay by six days (mean $1875/patient) would translate to an annual savings of $654,375 in hospital charges, assuming 365 patients received aminoglycoside therapy per year.

AB - The present study was a retrospective, case-control design aimed at evaluating whether the clinical pharmacokinetic service (CPS) is cost-effective, as assessed by lengths of hospital stay and aminoglycoside therapy, incidence of a decrease in renal function, and time for resolution of infection as determined by viral signs. Forty-six patients were entered into this study, and were matched by defined criteria. The results of the study demonstrated a six-day difference in hospital stay for the CPS group (p <0.05). Length of aminoglycoside therapy was 33 hours shorter for the CPS group. Additionally, the time necessary for resolution of the infection was significantly shorter for this group, as assessed by vital signs returning to normal or baseline. Three patients in each group expired. Two patients in the CPS group and five in the control group developed aminoglycoside-associated increases in serum creatinine. No significant difference was found between the two groups in age, weight, or APACHE II score. Additionally, the two groups were similar with respect to concomitant diseases and concomitant antibiotics used. The approximate cost of the CPS was calculated as $56 per patient. Use of the CPS decreasing hospital stay by six days (mean $1875/patient) would translate to an annual savings of $654,375 in hospital charges, assuming 365 patients received aminoglycoside therapy per year.

UR - http://www.scopus.com/inward/record.url?scp=0024549364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024549364&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 33

EP - 38

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 1

ER -